Spectral Medical Inc. focuses on the development and commercialization of products for the treatment of septic shock in the United States, Italy, Ireland, Russia, and internationally. The company markets Endotoxin Activity Assay, a rapid in-vitro diagnostic test for the detection of components of gram negative; and Polymyxin B-Hemoperfusion, a therapeutic hemoperfusion device that removes endotoxin from the bloodstream. It also develops, manufactures, and markets monoclonal and polyclonal antibodies, recombinant cardiac proteins, antibodies, and calibrators for use in the research and development, as well as products that are manufactured by other diagnostic companies. The company was formerly known as Spectral Diagnostics Inc. and changed its name to Spectral Medical Inc. in December 2014. Spectral Medical Inc. was incorporated in 1991 and is headquartered in Toronto, Canada.
Frequently asked questions
What sector does SPECTRAL MEDICAL (SD4) operate in?
SPECTRAL MEDICAL belongs to the Healthcare sector and operates in the Diagnostics & Research industry.
What is SPECTRAL MEDICAL (SD4) current stock price?
As of the latest data, SPECTRAL MEDICAL stock price is €0.62, with a previous close of €0.68. SPECTRAL MEDICAL lost -€0.06 in the last trading session, representing a -8.15% loss.
What is SPECTRAL MEDICAL (SD4) current market capitalization?
SPECTRAL MEDICAL market cap is approximately 182.00 million.
What is SPECTRAL MEDICAL (SD4) Earnings Per Share (EPS)?
The trailing EPS is -€0.07.
What is SPECTRAL MEDICAL (SD4) EBITDA?
SPECTRAL MEDICAL EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is 1.31 million.
Does SPECTRAL MEDICAL (SD4) pay dividends?
No. SPECTRAL MEDICAL does not pay a dividend.
When is SPECTRAL MEDICAL (SD4) next earnings report?
SPECTRAL MEDICAL is expected to release its next earnings report on September 30, 2026.
What is SPECTRAL MEDICAL (SD4) beta (volatility) score?
SPECTRAL MEDICAL has a beta of 0.221, indicating lower volatility than the overall market.
